• Amanda Grant-Orser, Amy Metcalfe, Janet E Pope, and Kerri A Johannson.
• Division of Respirology, Department of Medicine, University of Calgary, Calgary, AB, Canada. Electronic address: amanda.grant-orser@mail.mcgill.ca.
• Chest. 2022 Nov 1; 162 (5): 109311051093-1105.

AbstractAdvances in our understanding of interstitial lung disease (ILD) pathophysiology and natural history have led to the development of guidelines for the diagnosis and management of several of these complex diseases. The demographics of patients with ILD indicate the disease is not restricted to older adults. Connective tissue disease-associated ILD, familial pulmonary fibrosis, and post-COVID-19 fibrosis may affect women of child-bearing age. Recent trials have excluded pregnant women, thereby limiting the applicability of contemporary therapeutic advances to these patients. This review synthesizes the current knowledge of pregnancy outcomes in those with ILD, with a focus on connective tissue disease-associated ILD, and potential treatment implications for patients with ILD who are pregnant or considering pregnancy. Pregnancy considerations for patients with ILD include the need for preconception counseling and planning to ensure disease stability, medication and vaccination optimization, and multidisciplinary involvement of a patient's pulmonologist, obstetrician, and, when indicated, rheumatologist and genetic counselor. Evidence to date suggests that women with ILD can have safe and healthy pregnancies but that complications may occur in those with severe ILD.Copyright © 2022 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

15 keywords...

hide…